The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up.

MedStar author(s):
Citation: Gynecologic Oncology Reports. 20:47-50, 2017 MayPMID: 28317007Institution: MedStar Washington Hospital CenterDepartment: Obstetrics and GynecologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: PubMed-not-MEDLINE -- Not indexedYear: 2017ISSN:
  • 2352-5789
Name of journal: Gynecologic oncology reportsAbstract: *NACT use among SGO members for ovarian cancer is explored given recent trials.*Fewer SGO members feel they can't predict optimal cytoreduction pre-operatively.*Laparoscopy use has increased both for diagnosis and treatment of ovarian cancer.*Very high optimal cytoreduction rates are reported from SGO members.*Despite recent studies, SGO members don't regularly treat patients with NACT/ID.All authors: Ahmed A, Dewdney S, Huelsmann E, Zighelboim IFiscal year: FY2017Digital Object Identifier: Date added to catalog: 2017-05-06
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 28317007 Available 28317007

*NACT use among SGO members for ovarian cancer is explored given recent trials.*Fewer SGO members feel they can't predict optimal cytoreduction pre-operatively.*Laparoscopy use has increased both for diagnosis and treatment of ovarian cancer.*Very high optimal cytoreduction rates are reported from SGO members.*Despite recent studies, SGO members don't regularly treat patients with NACT/ID.

English

Powered by Koha